Characteristics associated with subjective and objective measures of treatment success in women undergoing percutaneous tibial nerve stimulation vs sham for accidental bowel leakage.

Accidental bowel leakage Fecal incontinence Patient-centered outcomes Percutaneous tibial nerve stimulation St Mark’s score Treatment success definition

Journal

International urogynecology journal
ISSN: 1433-3023
Titre abrégé: Int Urogynecol J
Pays: England
ID NLM: 101567041

Informations de publication

Date de publication:
08 2023
Historique:
received: 07 09 2022
accepted: 25 11 2022
medline: 11 8 2023
pubmed: 28 1 2023
entrez: 27 1 2023
Statut: ppublish

Résumé

In randomized trials both percutaneous tibial nerve stimulation (PTNS) and sham result in clinically significant improvements in accidental bowel leakage (ABL). We aimed to identify subgroups who may preferentially benefit from PTNS in women enrolled in a multicenter randomized trial. This planned secondary analysis explored factors associated with success for PTNS vs sham using various definitions: treatment responder using three cutoff points for St. Mark's score (≥3-, ≥4-, and ≥5-point reduction); Patient Global Impression of Improvement (PGI-I) of ≥ much better; and ≥50% reduction in fecal incontinence episodes (FIEs). Backward logistic regression models were generated using elements with significance of p<0.2 for each definition and interaction terms assessed differential effects of PTNS vs sham. Of 166 women randomized, 160 provided data for at least one success definition. Overall, success rates were 65% (102 out of 158), 57% (90 out of 158), and 46% (73 out of 158) for ≥3-, ≥4-, and ≥5-point St Mark's reduction respectively; 43% (68 out of 157) for PGI-I; and 48% (70 out of 145) for ≥50% FIEs. Of those providing data for all definitions of success, 77% (109 out of 142) met one success criterion, 43% (61 out of 142) two, and 29% (41 out of 142) all three success criteria. No reliable or consistent factors were associated with improved outcomes with PTNS over sham regardless of definition. Despite exploring diverse success outcomes, no subgroups of women with ABL differentially responded to PTNS over sham. Success results varied widely across subjective and objective definitions. Further investigation of ABL treatment success definitions that consistently and accurately capture patient symptom burden and improvement are needed.

Identifiants

pubmed: 36705728
doi: 10.1007/s00192-022-05431-y
pii: 10.1007/s00192-022-05431-y
pmc: PMC10372194
mid: NIHMS1887022
doi:

Types de publication

Randomized Controlled Trial Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1715-1723

Subventions

Organisme : NICHD NIH HHS
ID : UG1 HD069013
Pays : United States
Organisme : NICHD NIH HHS
ID : U10 HD054214
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD069006
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD069010
Pays : United States
Organisme : NICHD NIH HHS
ID : U10 HD041267
Pays : United States
Organisme : NICHD NIH HHS
ID : U10 HD054241
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD054214
Pays : United States
Organisme : NICHD NIH HHS
ID : U10 HD069010
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD041267
Pays : United States
Organisme : NICHD NIH HHS
ID : U10 HD054136
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD041261
Pays : United States
Organisme : NICHD NIH HHS
ID : U24 HD069031
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD054241
Pays : United States

Investigateurs

Halina M Zyczynski (HM)
Holly E Richter (HE)
Vivian W Sung (VW)
Emily S Lukacz (ES)
Lily A Arya (LA)
David D Rahn (DD)
Anthony G Visco (AG)
Donna Mazloomdoost (D)
Benjamin Carper (B)
Marie G Gantz (MG)

Informations de copyright

© 2023. The Author(s).

Références

Bharucha AE, Dunivan G, Goode PS, et al. Epidemiology, pathophysiology, and classification of fecal incontinence: State of the Science Summary for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) workshop. Am J Gastroenterol. 2015;110:127–36.
doi: 10.1038/ajg.2014.396 pubmed: 25533002
Dunivan GC, Chen CCG, Rogers R. ACOG Practice Bulletin No. 210: fecal incontinence. Obstet Gynecol. 2019;133:E260–73. https://doi.org/10.1097/AOG.0000000000003187 .
doi: 10.1097/AOG.0000000000003187
Brown HWW, Wexner SDD, Segall MMM, et al. Accidental bowel leakage in the mature women’s health study: prevalence and predictors. Int J Clin Pract. 2012;66:1101–8. https://doi.org/10.1111/ijcp.12018 .
doi: 10.1111/ijcp.12018 pubmed: 23067034
Crowell MD, Schettler VA, Lacy BE, et al. Impact of anal incontinence on psychosocial function and health-related quality of life. Dig Dis Sci. 2007;52:1627–31. https://doi.org/10.1007/s10620-006-9249-3 .
doi: 10.1007/s10620-006-9249-3 pubmed: 17211712
Brown HW, Wexner SD, Segall MM, et al. Quality of life impact in women with accidental bowel leakage. Int J Clin Pract. 2012;66:1109–16. https://doi.org/10.1111/ijcp.12017 .
doi: 10.1111/ijcp.12017 pubmed: 23067035
Paquette IM, Varma MG, Kaiser AM, et al. The American Society of Colon and Rectal Surgeons’ clinical practice guideline for the treatment of fecal incontinence. Dis Colon Rectum. 2015;58:623–36.
doi: 10.1097/DCR.0000000000000397 pubmed: 26200676
Thin NN, Horrocks EJ, Hotouras A, et al. Systematic review of the clinical effectiveness of neuromodulation in the treatment of faecal incontinence. Br J Surg. 2013;100:1430–47. https://doi.org/10.1002/bjs.9226 .
doi: 10.1002/bjs.9226 pubmed: 24037562
Martinson M, MacDiarmid S, Black E. Cost of neuromodulation therapies for overactive bladder: percutaneous tibial nerve stimulation versus sacral nerve stimulation. J Urol. 2013;189:210–6. https://doi.org/10.1016/j.juro.2012.08.085 .
doi: 10.1016/j.juro.2012.08.085 pubmed: 23174264
Knowles CH, Horrocks EJ, Bremner SA, et al. Percutaneous tibial nerve stimulation versus sham electrical stimulation for the treatment of faecal incontinence in adults (CONFIDeNT): a double-blind, multicentre, pragmatic, parallel-group, randomised controlled trial. Lancet. 2015;386:1640–8. https://doi.org/10.1016/S0140-6736(15)60314-2 .
doi: 10.1016/S0140-6736(15)60314-2 pubmed: 26293315
Zyczynski HM, Richter HE, Sung VW, et al. Percutaneous tibial nerve stimulation vs sham stimulation for fecal incontinence in women: neuromodulation for accidental bowel leakage randomized clinical trial. Am J Gastroenterol. 2022;117:654–67. https://doi.org/10.14309/ajg.0000000000001605 .
doi: 10.14309/ajg.0000000000001605 pubmed: 35354778 pmcid: 8988447
Horrocks EJ, Chadi SA, Stevens NJ, et al. Factors associated with efficacy of percutaneous tibial nerve stimulation for fecal incontinence, based on post-hoc analysis of data from a randomized trial. Clin Gastroenterol Hepatol. 2017;15:1915–1921.e2. https://doi.org/10.1016/j.cgh.2017.06.032 .
doi: 10.1016/j.cgh.2017.06.032 pubmed: 28647458
Zyczynski HM, Arya LA, Lukacz ES, et al. Design of a randomized controlled trial of percutaneous posterior tibial nerve stimulation for the treatment of refractory fecal incontinence in women: the neuromodulation for accidental bowel leakage study. Female Pelvic Med Reconstr Surg. 2021;27:726–34. https://doi.org/10.1097/SPV.0000000000001050 .
doi: 10.1097/SPV.0000000000001050 pubmed: 33950027 pmcid: 8567096
Bols EMJ, Hendriks EJM, Deutekom M, et al. Inconclusive psychometric properties of the Vaizey score in fecally incontinent patients: a prospective cohort study. Neurourol Urodyn. 2010;29:370–7. https://doi.org/10.1002/nau.20758 .
doi: 10.1002/nau.20758 pubmed: 19634170
Zyczynski HM, Richter HE, Sung VW, et al. Performance, acceptability, and validation of a phone application bowel diary. Neurourol Urodyn. 2020;39:2480–9. https://doi.org/10.1002/nau.24520 .
doi: 10.1002/nau.24520 pubmed: 32960998 pmcid: 7680657
Block G, Gillespie C, Rosenbaum EH, Jenson C. A rapid food screener to assess fat and fruit and vegetable intake. Am J Prev Med. 2000;18:284–8. https://doi.org/10.1016/S0749-3797(00)00119-7 .
doi: 10.1016/S0749-3797(00)00119-7 pubmed: 10788730
Barber MD, Brubaker L, Nygaard I, et al. Defining success after surgery for pelvic organ prolapse. Obstet Gynecol. 2009;114:600–9. https://doi.org/10.1097/AOG.0b013e3181b2b1ae .
doi: 10.1097/AOG.0b013e3181b2b1ae pubmed: 19701041 pmcid: 2904469
Jelovsek JE, Gantz MG, Lukacz E, et al. Success and failure are dynamic, recurrent event states after surgical treatment for pelvic organ prolapse. Am J Obstet Gynecol, 2021;224:362.e1–11
doi: 10.1016/j.ajog.2020.10.009 pubmed: 33039390
Meyer I, Richter HE. Impact of fecal incontinence and its treatment on quality of life in women. Women Health. 2015;11:225–38.
doi: 10.2217/WHE.14.66
Richter HE, Jelovsek JE, Iyer P, et al. Characteristics associated with clinically important treatment responses in women undergoing nonsurgical therapy for fecal incontinence. Am J Gastroenterol. 2020;115:115–27. https://doi.org/10.14309/ajg.0000000000000482 .
doi: 10.14309/ajg.0000000000000482 pubmed: 31895722 pmcid: 7197976
Rogers RG, Bann CM, Barber MD, et al. The responsiveness and minimally important difference for the Accidental Bowel Leakage Evaluation questionnaire. Int Urogynecol J. 2020;31:2499–505. https://doi.org/10.1007/s00192-020-04367-5 .
doi: 10.1007/s00192-020-04367-5 pubmed: 32613557 pmcid: 7680270

Auteurs

Douglas Luchristt (D)

Duke University Medical Center, Durham, NC, USA.

Benjamin Carper (B)

RTI International, Research, Triangle Park, NC, USA.

Sunil Balgobin (S)

University of Texas Southwestern, Dallas, TX, USA.

Isuzu Meyer (I)

University of Alabama at Birmingham, Birmingham, AL, USA.

Deborah Myers (D)

Brown University, Women's & Infants Hospital, Providence, RI, USA.

Donna Mazloomdoost (D)

Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, USA.

Marie Gantz (M)

RTI International, Research, Triangle Park, NC, USA.

Uduak Andy (U)

University of Pennsylvania, Philadelphia, PA, USA.

Halina M Zyczynski (HM)

Magee-Womens Research Institute, University of Pittsburgh, Pittsburgh, PA, USA.

Emily S Lukacz (ES)

University of California San Diego, La Jolla, CA, USA. elukacz@ucsd.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH